This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Genetic Counseling/ Testing/ Therapy  • Prostate Disease  • Oncology  • Prostate Cancer  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2006;295:2234-2238.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

After cancer diagnosis and treatment, the most looming concern expressed by most patients is their risk of recurrence. In the case of prostate cancer, despite screening techniques that include physical examinations, prostate-specific antigen (PSA) tests, and Gleason scoring (a grading system based on cancer cells' appearance under a microscope), oncologists often struggle with accurately stratifying patients as low-, intermediate-, and high-risk. For example, it is not clear why, following prostatectomy, some men's PSA levels rise again while others' do not.

Scientists have been looking for prognostic indicators that might predict which patients will benefit the most from the most aggressive treatment to ward off relapse. Studies presented at the annual meeting of the American Association for Cancer Research have found several candidate markers.

GENETIC HINTS

To look for genetic clues to individuals' outcomes, researchers from Illumina Inc and the University of California, both in San Diego, analyzed formalin-fixed, paraffin-embedded . . . [Full Text of this Article]